Cargando…

Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio

BACKGROUND: There remains a significant need to eliminate the risk of recurrence of resected cancers. Cancer vaccines are well tolerated and activate tumor-specific immune effectors and lead to long-term survival in some patients. We hypothesized that vaccination with alphaviral replicon particles e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crosby, Erika J, Hobeika, Amy C, Niedzwiecki, Donna, Rushing, Christel, Hsu, David, Berglund, Peter, Smith, Jonathan, Osada, Takuya, Gwin III, William R, Hartman, Zachary C, Morse, Michael A, Lyerly, Herbert Kim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661359/ https://www.ncbi.nlm.nih.gov/pubmed/33177177 http://dx.doi.org/10.1136/jitc-2020-001662

Ejemplares similares

Phase I study of alphaviral vector (AVX701) in colorectal cancer patients: comparison of immune responses in stage III and stage IV patients
por: Morse, Michael A, et al.
Publicado: (2015)

Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody
por: Osada, T, et al.
Publicado: (2010)

Combination of a novel heat shock protein 90-targeted photodynamic therapy with PD-1/PD-L1 blockade induces potent systemic antitumor efficacy and abscopal effect against breast cancers
por: Kaneko, Kensuke, et al.
Publicado: (2022)

Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity
por: Abe, Shinya, et al.
Publicado: (2022)

Clinical trials of self-replicating RNA-based cancer vaccines
por: Morse, Michael A., et al.
Publicado: (2023)

Beyond Neoantigens: Antigens Derived from Tumor Drivers as Cancer Vaccine Targets
por: Crosby, Erika J., et al.
Publicado: (2023)

Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis
por: Knitz, Michael W, et al.
Publicado: (2021)

Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer
por: Revenko, Alexey, et al.
Publicado: (2022)

The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation
por: Sum, Eva, et al.
Publicado: (2022)

Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression
por: Hwang, Bin-Jin, et al.
Publicado: (2022)

SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
por: Redin, Esther, et al.
Publicado: (2021)

IMMU-10. INTERIM ANALYSIS OF THE HIT-HGG REZ IMMUNVAC STUDY - DENDRITIC CELL VACCINATION WITH PARTIAL TREG DEPLETION IN CHILDREN, ADOLESCENTS, AND ADULTS WITH RELAPSED HIGH-GRADE GLIOMAS
por: Eyrich, Matthias, et al.
Publicado: (2020)

P059: Multi-effector cell targeting with half-life extended bispecific scFv in Hodgkin lymphoma
por: Shi, Zhiyuan, et al.
Publicado: (2022)

p50 suppresses cytotoxic T lymphocyte effector function to regulate tumor immune escape and response to immunotherapy
por: Lu, Chunwan, et al.
Publicado: (2020)

P07 Toxicokinetic profile of VRP-034
por: Murkunde, Yogeshkumar Vishnupant, et al.
Publicado: (2022)

Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2
por: Morse, Michael A, et al.
Publicado: (2007)

IMMU-07. IMMUNE EFFECTOR CELL ASSOCIATED NEUROTOXICITY (ICANS) AMONG PEDIATRIC AND AYA PATIENTS: MD ANDERSON CANCER CENTER EXPERIENCE
por: Brown, Brandon, et al.
Publicado: (2020)

Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer
por: Trüb, Marta, et al.
Publicado: (2020)

Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders – Advances and challenges
por: Goswami, Tapas Kumar, et al.
Publicado: (2022)

P06 Pharmacokinetics and renal accumulation of VRP-034
por: Vishwakarma, Kamlesh Kumar, et al.
Publicado: (2022)

INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responses
por: Sulzmaier, Florian J, et al.
Publicado: (2023)

Expanded antigen-experienced CD160(+)CD8(+)effector T cells exhibit impaired effector functions in chronic lymphocytic leukemia
por: Bozorgmehr, Najmeh, et al.
Publicado: (2021)

Combination of cancer vaccine with CD122-biased IL-2/anti-IL-2 Ab complex shapes the stem-like effector NK and CD8(+) T cells against tumor
por: Shimizu, Kanako, et al.
Publicado: (2023)

Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers
por: Osada, Takuya, et al.
Publicado: (2018)

Oncolytic alphavirus SFV-VA7 efficiently eradicates subcutaneous and orthotopic human prostate tumours in mice
por: Martikainen, Miika, et al.
Publicado: (2017)

Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
por: Yoo, Changhoon, et al.
Publicado: (2020)

Optimization of vaccine responses with an E1, E2b, E3 deleted Ad5 vector circumvents pre-existing anti-vector immunity
por: Osada, Takuya, et al.
Publicado: (2009)

VRP in urban areas to optimize costs while mitigating environmental impact
por: Cerrone, Carmine, et al.
Publicado: (2022)

4-1BBL–containing leukemic extracellular vesicles promote immunosuppressive effector regulatory T cells
por: Swatler, Julian, et al.
Publicado: (2022)

Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates
por: Liao, John B, et al.
Publicado: (2021)

Fractionated (131)I anti-CEA radioimmunotherapy: effects on xenograft tumour growth and haematological toxicity in mice
por: Violet, J A, et al.
Publicado: (2008)

Dose-Finding Study of a CEA-Targeting Agent, SGM-101, for Intraoperative Fluorescence Imaging of Colorectal Cancer
por: de Valk, Kim S., et al.
Publicado: (2020)

P05 In vivo efficacy of VRP-034 in lung and thigh infection models
por: Vishwakarma, Kamlesh Kumar, et al.
Publicado: (2022)

CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells
por: Martens, Anne W J, et al.
Publicado: (2020)

CD71(+) erythroid cells suppress T-cell effector functions and predict immunotherapy outcomes in patients with virus-associated solid tumors
por: Bozorgmehr, Najmeh, et al.
Publicado: (2023)

A(2B) adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models
por: Tay, Apple Hui Min, et al.
Publicado: (2022)

Immune checkpoint inhibitor-associated celiac disease
por: Badran, Yousef R, et al.
Publicado: (2020)

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study
por: Oaknin, Ana, et al.
Publicado: (2022)

Geospatial characterization of immune cell distributions and dynamics across the microenvironment in clear cell renal cell carcinoma
por: Chakiryan, Nicholas H, et al.
Publicado: (2023)

Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist
por: Meneveau, Max O, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h4cis5hmtcci34g6n7edbk9eva